Expert Opinion on Investigational Drugs

Article	Citations
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL	116
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men	84
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	80
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD	75
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	74
Theranostic strategies in sarcoma: preliminary clinical evidence	74
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	67
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	62
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	59
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	56
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	52
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	43
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	39
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	38
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	37
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	32
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development	32
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	32
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies	32
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials	30
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?	29
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets	28
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors	27
Endothelin receptor antagonists for diabetic kidney disease: back to the future?	26
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials	24

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su	23
Potassium channel modulators and schizophrenia: an overview of investigational drugs	22
Investigational drugs for the treatment of dysmenorrhea	21
Duchenne muscular dystrophy: promising early-stage clinical trials to watch	20
Emerging treatments for chronic urticaria	20
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia	20
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease	20
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development	19
Current options and investigational drugs for the treatment of eosinophilic esophagitis	19
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer	18
Recent developments in adjunct therapies for type 1 diabetes	18
IgA nephropathy: an overview of drug treatments in clinical trials	18
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer	17
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials	17
Investigational drugs for immune thrombocytopenia	17
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics	17
Current experimental and early investigational agents for cardiac fibrosis: where are we at?	16
NF1 alterations in cancers: therapeutic implications in precision medicine	16
Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1	16
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options	16
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration	16
Investigational new drugs for the treatment of leishmaniasis	16
Novel systemic treatment approaches for metastatic pancreatic cancer	15
Preclinical therapeutics for sickle cell disease: modern developments and future considerations	15
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists	15
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal	15
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer	15
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study	15
What is the progress of experimental drug development for fibromyalgia?	15
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials	14
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects	14
Frontotemporal dementia: from genetics to therapeutic approaches	14
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations	14
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021	13
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)	13
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents	13
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease	13
Assessing the clinical progress of the bispecific nanobody sonelokimab	13
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)	13
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions	13
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps	12
Navafenterol for chronic obstructive pulmonary disease therapy	12
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici	12
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	12
Investigational drugs for the treatment of olfactory dysfunction	12
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa	12
JAK inhibitors for rheumatoid arthritis	12
Investigational agents for pancreatic neuroendocrine tumors: what clinical progress have we seen in the last 5 years?	11
JAK inhibitors in crohn’s disease: ready to go?	11
Investigational thrombolytic drugs for acute ischemic stroke	11

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents	11
Immunotherapeutic strategies for treating opioid use disorder and overdose	11
Clinical development of tri-specific antibodies for immune-oncology	11
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia	11
Investigational new drugs for the treatment of Dravet syndrome: an update	11
Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies	11
Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials	11
Inflammatory myopathies: shedding light on promising agents and combination therapies in clinical trials	11
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers	10
Investigational agents for ischaemic cardiomyopathy treatment: preclinical and early phase insights	10
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis	10
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer	10
The impact of current investigational drugs for acne on future treatment strategies	10
Inflammation and Huntington’s disease – a neglected therapeutic target?	10
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study	10
Emerging agents for the treatment and prevention of stroke: progress in clinical trials	10
Pharmacological agents for bone fracture healing: talking points from recent clinical trials	10
Camrelizumab: an investigational agent for hepatocellular carcinoma	10
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies	10
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus	10
Islatravir: evaluation of clinical development for HIV and HBV	9
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-c	9
Prospects of current AXL-targeting therapies in early phase cancer trials	9
Assessing potential of psilocybin for depressive disorders	9
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma	9
Investigational anti IL-13 asthma treatments: a 2023 update	9
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials	9
A VEGF gene therapy approach for the treatment of patients with coronary artery disease and refractory angina: assessment of clinical development	9
Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?	9
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections	9
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials	9
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress	9
Novel investigational drugs for alopecia areata and future perspectives	9
Mantle cell lymphoma: what clinical progress in the last 5 years?	9
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets	9
Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials	9
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep	9
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension	9
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs	9
Preclinical prospects of investigational agents for hearing loss treatment	9
Novel agents to treat adrenal insufficiency: findings of preclinical and early clinical trials	8
Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma	8
Investigational DNA topoisomerase I inhibitors for colorectal cancer: preclinical and early phase developments	8
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH	8
Investigational drugs in early clinical development for portal hypertension	8
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects	8
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate	8
Retinal stroke: research models, targets and experimental drugs	8
What have we learned from past failures of investigational drugs for Alzheimer’s disease?	8
Insights into the anti-inflammatory and anti-arthritic potential of 3-Acetyl-11-keto-β-Boswellic Acid as a therapeutic approach in Rheumatoid Arthritis	8
Will new investigational drugs change the way we treat Charcot-Marie-Tooth disease?	8
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects	7
Experimental drugs for the prevention or treatment of sensorineural hearing loss	7
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies	7
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review	7
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs	7
Fibroblast growth factor therapies in biliary tract cancers: current and future state	7
Investigational drugs for ischemic stroke: what’s in the clinical development pipeline for acute phase and prevention?	7
AXS-05: an investigational treatment for Alzheimer’s disease-associated agitation	7
Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis	7
Investigational drugs in early phase trials for myelofibrosis	7
Investigational drugs for the treatment of acromegaly: new agents to transform therapy	7
Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials	7
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension	7
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape	7
Bomedemstat as an investigative treatment for myeloproliferative neoplasms	7
Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease	7
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study	7
Psoriasis: talking points from recent clinical trials	7
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity	7
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects	6
Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications	6
Psoriasis: a focus on upcoming oral formulations	6
Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials	6
Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation	6
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?	6
Correction	6
Developments and challenges for new and emergent preparations for male hypogonadism treatment	6
Investigational new drugs to treat brain metastasis from non-small cell lung cancer	6
Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials	6

Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials	6
Retatrutide: a triple incretin receptor agonist for obesity management	6
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer	6
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study	6
Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects	6
Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: res	6
T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development	6
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled do	6
Emerging therapies for overactive bladder: preclinical, phase I and phase II studies	5
Investigational drugs inhibiting complement for the treatment of geographic atrophy	5
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action	5
A focused report on IFN-1 targeted therapies for lupus erythematosus	5
A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome	5
Zanzalintinib (XL092): a next-generation tyrosine kinase inhibitor—comprehensive review of early safety & efficacy data	5
Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials	5
Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics	5
First-in-human phase I studies of YJ001 spray applied to local skin in healthy subjects and patients with diabetic neuropathic pain	5
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation	5
Long COVID [post-acute sequelae of coronavirus disease 2019]: experimental drugs for cardiopulmonary complications	5
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study	5
A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion prote	5
Clinical development of BPS804 for osteogenesis imperfecta: from failure to fruition?	5
Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure	4
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension	4
Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseases	4
Polyvalent immunoglobulin therapy: preclinical evidence and potential for treating chemotherapy-induced peripheral neuropathy	4
Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease	4
Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments	4
Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation	4
Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer	4
Novel investigational treatments for ventilator-associated pneumonia and critically ill patients in the intensive care unit	4
Prospect of CAR T-cell therapy in acute myeloid leukemia	4
KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases	4
Insulin sensitizers in 2023: lessons learned and new avenues for investigation	4
Factor IX stimulants in preclinical and early phase trials for hemophilia B treatment	4
Venetoclax in acute myeloid leukemia	4
Early stage clinical trials for the treatment of hemophilia A	4
Development of investigational radiotherapeutics for the diagnosis and treatment of glioma	4
Experimental and new investigational drugs for the treatment of uterine fibroids	4
Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline	4
ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease	4
Avasopasem for the treatment of radiotherapy-induced severe oral mucositis	4
Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection	4
Design strategy and research progress of multifunctional nanoparticles in lung cancer therapy	4
Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?	4
The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke	4
Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments	4
Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis	4
Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development	4